- Home
- / SIGA Technologies
SIGA Technologies
Stock Price
$7.1
2024-10-29
Market Capitalization
$507.4 M
2024-10-29
Revenue
$94.6 M
FY, 2025
SIGA Technologies Summary
Company Summary
- Overview
- SIGA Technologies is a biopharmaceutical company that develops treatments for infectious diseases. It offers TPOXX (tecovirimat), an antiviral medication used to treat smallpox, monkeypox, and other orthopoxviruses.
- Type
- Public
- Status
- Active
- Founded
- 1995
- HQ
- New York, NY, US | view all locations
- Website
- https://www.siga.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Robin E. Abrams, General Counsel and Chief Administrative Officer
Daniel J. Luckshire, Executive Vice President and Chief Financial Officer
Dennis E. Hruby, Executive Vice President and Chief Scientific Officer
LocationsView all
2 locations detected
New York, NY HQ
United States
31 East 62nd Street
Corvallis, OR
United States
4575 SW Research Way, Suite 110
SIGA Technologies Financials
Summary Financials
- Revenue (Q1, 2026)
- $6.2M
- Gross profit (Q1, 2026)
- $3.3M
- Net income (Q1, 2026)
- ($3.5M)
- Cash (Q1, 2026)
- $145.6M
- EBIT (Q1, 2026)
- ($5.3M)